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Abstract 
CRLF2 is a member of type I cytokine receptor 
family. CRLF2 forms a functional complex with IL-
7 receptor α chain and thymic stromal 
lymphopoietin, this complex induces the activation 
of signal transducers and activators of transcription 
proteins. The overexpression of CRLF2 induced by 
genetic rearrangements has been described in acute 
lymphoblastic leukemia. 
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Identity 
Other names: CRL2, TSLPR 
HGNC (Hugo): CRLF2 
Location: Xp22.33 and Yp11.2, negative strand. 
ENSG00000205755 
Local order 
CRLF2 is located on chromosome X and Y, on the 
short arm and lies between RPL14P5 (ribosomal 
protein L4 pseudogene 5) and CSF2RA (colony 
stimulating factor 2 receptor alpha subunit). Entrez 
Gene ID: 64109 
Figure 1. A) Chromosomal location of CRLF2 gene. B) Mapping of CRLF2 gene and local order on genomic context of the 
chromosome X and Y. 
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Figure 2. Chromosomes obtained from MHH-CALL-4 cell line positive to IGH/CRLF2 translocation detected by fluorescence in 
situ hybridization (FISH). The der(Y) chromosome is lost in the cell line. Metaphase hybridized with CRLF2 break-apart probe 
(Cytocell Aquarius) with a normal chromosome X (green-red signal, yellow arrow), and der(14) (green signal, white arrow). 
 
Figure 3. CRLF2 gene encodes four transcript variants: two with 8 exons, one with 9 exons, and one with 7 exons (exons are 
represented by violet boxes and introns by black line). ENSG00000205755, Entrez Gene ID: 64109 
 
DNA/RNA 
Description 
CRLF2 gene is located in reverse strand of pseudo-
autosomal region 1 (PAR1) in X and Y 
chromosomes. CRLF2 encompasses 22kb of DNA 
and give rise to four transcript variants with different 
lengths: 1.6, 1.5, 1.0 and 1.7 kb. ENSG00000205755 
Transcription 
CRLF2 gene encodes a member of type I cytokine 
receptor family and generate four transcript variants 
(Table 1). Three generate protein coding transcripts 
and one generates a non-sense mediated decay 
transcript.  
According with gene expression array data CRLF2 
is expressed, from highest to lowest, in: cervix > 
lung > bladder > small intestine > esophagus > 
stomach > skin > prostate > uterus > vagina > testes 
> colon > spleen > mammary gland > thyroid > 
whole blood.  
It has been reported that in pathological conditions 
the transcription rate of CRLF2 is altered. CRLF2 
overexpression (fold change > 2) is found in: 
microbial infection, immunodeficiency syndromes 
(X-linked hyper IgM syndrome), autoimmune 
diseases (arthritis), and cancer (esophagus dysplasia, 
papillary thyroid carcinoma and acute lymphoblastic 
leukemia). The CRLF2 subexpression (fold change 
< 2) has been reported only in cancer 
(myelodysplastic syndrome, non-small cell lung 
carcinoma, hepatobiliary carcinoma, colorectal 
carcinoma, pancreatic adenocarcinoma and breast 
carcinoma). ENSG00000205755; UniProt Q9HC73; 
neXtProt NX_Q9HC73 
Table 1. Transcript variants and proteins 
Name (RefSeq) Exons Coding Exons Transcript Length Protein Length Type of transcript 
CRLF2-203 (NM_022148) 8 8 1, 639 bp 371 residues Protein coding 
CRLF2-201 9 8 1, 545 bp 371 residues Protein coding 
CRLF2-202 (NM_001012288) 7 6 1, 013 bp 259 residues Protein coding 
CRLF2-204 (NR_110830) 8 5 1, 789 bp 232 residues Non-sense mediated decay 
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Figure 4. Isoform 1 is a single-pass type I membrane protein, have a length of 371 aa. Protein sequence includes four main 
regions: FN3 (Fibronectin type 3), encompassed from 109 to 207 aa; WSXWS motif, encompassed from 200 to 204 aa; Box 1 
motif encompassed from 261 to 269 aa; Transmembrane region encompassed from 232 to 252 aa. Isoform 2 is a secreted 
protein an only have FN3 region, encompassed from 7 to 76 aa. 
 
Protein 
Description 
CRLF2 gene encodes a member of the type I 
cytokine receptor family. CRLF2 has three protein 
coding transcripts: CRLF2-201, CRLF2-202, 
CRLF2-203 and CRLF2-204.  
CRLF2-203 and CRLF2-201 transcript variants 
generate the longer isoform of 371 amino acids (42 
kDa), also called isoform 1.  
Isoform 1 has the protein regions that characterize 
this family gene: FN3 (Fibronectin type 3) region, 
WSXWS motif, Box 1 motif, and transmembrane 
region. Post-translational modifications of CRLF2 
protein include glycosylation at asparagine residues 
(Asn169, Asn55 and Asn47) and phosphorylation at 
isoleucine (Ile271) and tyrosine (Tyr74) residues.  
The other isoform, called isoform 2, is encoded by 
the transcript variant CRLF2-202. This isoform is 
shorter, 259 amino acids (26.6 kDa), at N-terminus 
compared with isoform 1 because lacks an alternate 
exon which results in translation initiation at a 
downstream start codon. ENSG00000205755; 
UniProt Q9HC73, Q9HC73-2, Q4V300; neXtProt 
NX_Q9HC73 
Expression 
CRLF2 protein is present in intestine, bone marrow, 
spleen, thymus, and is more abundant in dendritic 
cells. neXtProt NX_Q9HC73 
Localisation 
CRLF2 isoform 1 is a cell membrane protein and 
CRLF2 isoform 2 is a secreted protein. 
Function 
CRLF2 forms a functional complex with IL-7Rα  
(IL-7 receptor α chain) and TSLP (thymic stromal 
lymphopoietin).  
Functional complex activation induces different 
signals depending on the type of cell and also exerts 
multiple functions. Heterocomplex is involved in a 
plethora of physiologic and pathologic immune 
functions, including: tolerance, allergy, autoimmune 
diseases and cancer. (Tsilingin et al., 2017).  
CRLF2 is expressed mainly in dendritic cells and 
also hematopoietic cells including T cells, B cells, 
granulocytes, and mast cells.  
Heterocomplex main function is the differentiation 
to T helper type 2 (Th2) cells. CRLF2-activated 
dendritic cells express OX40 ligand and trigger 
naive CD4+ to differentiate into inflammatory Th2 
cells and the expansion of allergen-specific Th2 
memory cells (Lin et al., 2018).  
According with phosphoproteome analysis in 
diverse cell types, after TSLP binds to the 
CRLF2/IL-7Rα heterocomplex, the phosphorylation 
of Janus kinase1 (JAK1) and 2 (JAK2) activates 
signal transducers and activators of transcription 
(STATs) proteins, including: STAT1, STAT3, 
STAT4, STAT5A, STAT5B and STAT6. 
Heterocomplex also activates other signaling 
molecules such as PI3K/AKT/MTOR pathway, SRC 
/ TEC pathway, MAPK3 / MAPK1 (ERK1/2), NF-
kB, MAPK8 / MAPK9 (JNK1 JNK2), and 
p38/MAPK activation (Zhong Jun et al., 2012; 
Zhong Jun et al., 2014).  
In allergy or autoimmune disease has been described 
high expression of TSLP and overstimulation of 
TSLP/CRLF2/IL-7Rα complex. Tezepelumab is a 
human monoclonal antibody that blocks functional 
complex and is successfully used in asthma 
treatment (Van Rompaey et al., 2012).  
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Figure 5. A) TSLP /CRLF2/ IL7R complex activation is implicated in Th2 differentiation. TSLP binds to CRLF2/IL-7Rα 
heterodimer in dendritic cells and promotes the expression of OX40 ligand ( TNFSF4 (CD252)) and IL13, IL5, IL4 and TNF to 
induce Th2 differentiation. B) TSLP/CRLF2/IL-7Rα complex activation in dendritic cells. Activation of CRLF2 was described by 
first time in dendritic cells. This scheme exemplifies the main nodes involved. 
 
The role of functional heterocomplex in cancer is 
still controversial, in certain neoplasia plays a pro-
tumorigenic role, whereas in others, a protective 
role.  
For example, in cervix, breast, and pancreas cancer 
has been describe an increase of metastasis 
associated with an overstimulation of 
TSLP/CRLF2/IL-7Rα. On the other hand, in colon 
and skin carcinoma, functional heterocomplex has  
been associated with better prognostic. In addition  
to above, CRLF2 gene has genetic alterations that 
promote cell survival in cancer.  
The genetic rearrangements P2RY8/CRLF2 and 
IGH/CRLF2, generate CRLF2 overexpression, and 
the mutation Phe232Cys, encodes CRLF2 proteins 
capable of forming homodimers and self-activation, 
both described in acute lymphoblastic leukemia 
(Varricchi et al., 2018; Zhong Jun, 2014). 
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Figure 6. C)  Phosphoproteomic analysis reveals multiple targets in TSLP/CRLF2/IL-7Rα pathway in different cell types. This 
scheme shows experimental curated data obtained from NetSlim. 
Homology 
 
Table 2. CRLF2 Orthologues 
Name Organism 
CRLF2  P. troglodytes 
CRLF2 (ENSCAFG00000011034)   C. lupus 
LOC529792 (ENSBTAG00000020242)   B. taurus 
Crlf2 (ENSMUSG00000033467)   M. musculus 
Crlf2 (ENSRNOG00000049828)   R. novergicus 
LOC418668 (ENSGALG00000016696)   G. gallus 
Mutations 
See Figure 7. 
 
 
 
 
Figure 7. Mutations in CRLF2 have been identified in a 
wide range of cancer types. Most of them are missense 
mutations (green), nonsense mutations are also 
represented (violet).Somatic 
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CDS Mutation  Cancer Type 
Type of 
Mutation 
c.315C>A Bladder Carcinoma Missense 
c.357C>A Bladder Carcinoma Missense 
c.193G>A Bladder Carcinoma Missense 
c.89T>A Bladder Carcinoma Missense 
c.33C>G 
Diffuse Large B 
Cell Lymphoma 
Missense 
c.415T>C 
Diffuse Large B 
Cell Lymphoma 
Missense 
c.349C>T Osteosarcoma Missense 
c.330T>C Colon Carcinoma Missense 
c.384G>A Colon Carcinoma Missense 
c.33C>G Colon Carcinoma Missense 
c.159G>A Rectum Carcinoma Missense 
c.474C>T Adenocarcinoma Missense 
c.372C>T Adenocarcinoma Missense 
c.411G>A Adenocarcinoma Missense 
c.603C>T Adenocarcinoma Missense 
c.405G>A Adenocarcinoma Missense 
c.669G>A Adenocarcinoma Missense 
c.642T>C Adenocarcinoma Missense 
c.642T>C 
Endometrioid 
Carcinoma 
Missense 
c.321C>T Lung Carcinoma Missense 
c.384G>A Pleura Carcinoma Missense 
c.456C>T Melanoma Missense 
c.411G>A Melanoma Missense 
c.468C>T Melanoma Missense 
c.123C>T Melanoma Missense 
c.630G>A Melanoma Missense 
c.534G>A Melanoma Missense 
c.438C>T Melanoma Missense 
c.383C>T 
Merkel Cell 
Carcinoma 
Missense 
c-.335G>T 
Merkel Cell 
Carcinoma 
Missense 
c.604G>A 
Urinary Tract 
Carcinoma 
Missense 
c.742C>A 
Urinary Tract 
Carcinoma 
Missense 
c.208C>A Neuroblastoma Missense 
c.139A>T Glioma Missense 
c.404C>T Glioma Missense 
c.365C>T Glioma Missense 
c.598C>A Glioma Missense 
c.404C>T Glioma Missense 
c.313C>T Glioma Missense 
c.74G>A Glioma Missense 
c.632G>A Glioma Missense 
c.445G>A Meningioma Missense 
c.660G>T Breast Carcinoma Missense 
c.734C>T Breast Carcinoma Missense 
c.526G>C Breast Carcinoma Missense 
c.297C>G Cervix Carcinoma Missense 
c.658G>C Cervix Carcinoma Missense 
c.566C>T 
Endometrium 
Carcinoma 
Missense 
c.536A>T
Endometrium 
Carcinoma 
Missense 
c.643C>T 
Endometrium 
Carcinoma 
Missense 
c.7C>T 
Endometrium 
Carcinoma 
Missense 
c.496A>C 
Endometrium 
Carcinoma 
Missense 
c.373G>A 
Endometrium 
Carcinoma 
Missense 
c.346T>C 
Endometrium 
Carcinoma 
Missense 
c.495A>C 
Endometrium 
Carcinoma 
Missense 
c.248G>T Kidney Carcinoma Missense 
c.526G>A Liver Carcinoma Missense 
c.105C>G Liver Carcinoma Missense 
c.671C>T 
Acute Myeloid 
Leukemia 
Missense 
c.695T>G 
B Cell Acute 
Lymphoblastic 
Leukemia  
Missense 
c.2T>A 
Mantle Cell 
Lymphoma 
Missense 
c.340G>C 
Marginal Zone 
Lymphoma 
Missense 
c.228C>T 
Head and Neck 
Carcinoma 
Missense 
c.764G>A Melanoma No sense 
c.764G>A Melanoma No sense 
c.755G>A 
Head and Neck 
Carcinoma 
No sense 
c.755G>A Melanoma No sense 
c.451C>T Melanoma No sense 
c.628C>T Pancreas No sense 
c.137G>A Colon Carcinoma No sense 
c.620C>G 
Intestinal 
Adenocarcinoma 
No sense 
c.91C>T 
Glioblastoma 
Multiforme 
No sense 
c.73G>T Adenocarcinoma No sense 
c.54G>A 
Head and Neck 
Carcinoma 
No sense 
c.25G>T Lung Carcinoma No sense 
Table 3 CRLF2 mutations in cancer 
Catalogue of Somatic Mutations in Cancer; cBioPortal for 
Cancer Genomics 
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Implicated in 
Hematological malignancies 
Oncogenesis 
The t(X;14)(p22;q32) or t(Y;14)(p11;q32) rearrange 
CRLF2 with immunoglobulin heavy chain gene 
forming IGH/CRLF2 rearrangement. With P2Y 
purinoceptor 8 gene ( P2RY8), located also in the 
pseudoautosomal (PAR1) region of X or Y 
chromosomes, CRLF2 forms a rearrangement 
through the interstitial deletions del(X)(p22p22) or 
del(Y)(p11p11). Both abnormalities are associated 
with B-precursor acute lymphoblastic leukemia (pre-
B ALL) and Down syndrome pre-B ALL (Entrez 
Gene ID: 64109; Russell LJ et al., 2009).  
It has been referred similar deletions in the PAR1 
region involving the interleukin 3 receptor subunit 
alpha ( IL3RA) gene or the colony stimulating factor 
2 receptor alpha subunit (CSF2RA) gene and 
CRLF2, indicating that the breakpoints are variable 
between patients. Interestingly, one patient has been 
reported with the CSF2RA/CRLF2 rearrangement 
and IGH/ EPOR (Yano M et al., 2015). These 
rearrangements produce the overexpression of 
CRLF2 by the juxtaposition of this gene within the 
gene promoter of P2RY8, AKAP17A (SFRS17A), 
or ASMT (Russell LJ et al., 2009). Biallelic 
deletions of the PAR1 region, including CSF2RA 
and CRLF2 genes, have been reported in mantle cell 
lymphoma (Nieländer I et al., 2008).  
In addition, four fusions with CRLF2 have been also 
reported: 1) CHRFAM7A /CRLF2 with the 
cholinergic receptor, nicotinic, alpha 7, exons 5-10 
and he family with sequence similarity 7A, exons A-
E fusion gene (CHRNA7) located in 15q13 (Fusion 
gen ID: 7161); 2) CRLF2/ U2AF1 with the U2 small 
nuclear RNA auxiliary factor 1 gene (U2F1), 
associated with myelodysplastic syndrome, and 
located in 21q22.3 (Fusion gen ID: 8499); 3) 
GOLGA8A /CRLF2 with the golgin A8 family 
member A gene (GOLGA8A) in 15q14 (Fusion gen 
ID: 15056); 4) WDR27 /CRLF2 with the WD repeat 
domain 27 gene (WDR27) in 6q27 (Fusion gen ID: 
41824). 
Pulmonary alveolar proteinosis 
A recessive pattern of another similar homozygous 
deletion, that disrupts CSF2RA, CRLF2, and IL3RA 
gene, was found in a boy with pulmonary alveolar 
proteinosis, an accumulation of surfactant in the 
alveoli. Surfactant is cleared by alveolar 
macrophages, and granulocyte-macrophage colony-
stimulating factor (GM-CSF) and its signaling is 
necessary for this process. GM-CSF activates Jak-
Stat pathway inducing phagocytic functions of 
alveolar macrophage and catabolize surfactant (Chiu 
CY et al., 2017). 
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